Audit in process? Call the number on your audit letter to get options.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 14, 2018 - The FDA announced the approval of Janssen Biotech’s Erleada (apalutamide), for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC).
Download PDF
Return to publications
